Side-by-side · Research reference
ChonlutenvsPE 22-28
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BAnimal-StrongHUMAN-REVIEWED16/47 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
PE 22-28
TREK-1 Antagonist · Pre-Clinical
IP · SQ · Once Daily (animal models)Djillani 2017Pietri 2019
01Mechanism of Action
Parameter
Chonluten
PE 22-28
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
TREK-1 two-pore-domain potassium channelDjillani 2017Ma 2020
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
TREK-1 channel blockade → Neuronal membrane depolarisation → Enhanced hippocampal excitability → Increased neuroplasticity
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Antidepressant-like activity in forced swim test and tail suspension test; reduced A1-like reactive astrocyte activation; neuroprotection via NF-κB pathway modulationDjillani 2017Cong 2023Wu 2021
Feedback intact?
—
N/A — direct ion channel blockade; not receptor-mediated endocrine axis
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Synthetic truncation of spadin (PE 12-28), itself derived from the sortilin propeptide C-terminus. Residues 22-28: Val-Val-Arg-Gly-Trp-Leu-Arg.Djillani 2017Mazella 2018
Antibody development
—
Not reported in animal studies
02Dosage Protocols
Parameter
Chonluten
PE 22-28
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
Once daily
Sustained antidepressant effect over 7+ days.
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Evidence basis
In vitro mechanistic
Multiple rodent RCTs; behavioral + electrophysiology endpointsDjillani 2017Qi 2018Wu 2021
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
—
Clinical validation
None (PubMed indexed)
—
Animal dose (antidepressant)
—
0.3–3 µg/kg IP
Effective in forced swim test, tail suspension test, CUMS models.
Animal dose (neuroprotection)
—
0.03 µg/kg IPPietri 2019
Low-dose TREK-1 activation post-stroke for 7 days, then high-dose blockade.
Onset (animal)
—
Within hours (acute); full effect 4–7 days
Comparison to fluoxetine
—
PE 22-28 outperforms fluoxetine in CUMS-sensitive rats by day 7
Chronic administration shows superior long-term efficacy.
Human equivalent (extrapolated)
—
Not established — no clinical trials
Allometric scaling from rodent data unavailable.
04Side Effects & Safety
Parameter
Chonluten
PE 22-28
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Toxicity (animal)
—
No adverse effects reported at therapeutic doses
Cardiovascular (theoretical)
—
TREK-1 expressed in cardiac tissue; arrhythmia risk unclear
Weight change
—
Not reported in animal studies
Neurological
—
No seizures or behavioral abnormalities noted
Long-term safety
—
Unknown — longest animal study 28 days
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
PE 22-28
- ·Human use — no clinical safety data available
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
PE 22-28
- ·Cardiac arrhythmia or channelopathy (theoretical TREK-1 cardiac role)
05Administration Protocol
Parameter
Chonluten
PE 22-28
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Dissolved in sterile saline or vehicle. Intraperitoneal injection, 0.3–3 µg/kg body weight. Once daily administration in rodent behavioral studies.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Shorter peptide length (7 AA) confers improved plasma stability vs 17-AA spadin. Exact storage conditions not detailed in published protocols.Djillani 2017
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Enhanced CNS bioavailability vs full spadin, likely due to smaller size. Mechanism (passive diffusion vs active transport) not fully characterized.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Not established — peptide synthesis methods for research use only. No pharmaceutical-grade formulation available.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
—